CTLA4 and neoplasm: By contrast, the percentage of R1 tumor-derived monocytes was higher in combo treated as compared to IgG treated controls or matched spleens (Figures 5D, E), while the infiltrating monocytes from anti-PD-1/CTLA-4 treated tumors had decreased levels of R2 and R3 monocytes (Figures 5D, E).